文献速递皮肤肿瘤

转移性黑色素瘤患者联合使用质子泵抑制剂与BRAF/MEK抑制剂

The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
PubMed 文献 · Br J Dermatol · 2023-01-01

基于法国国家健康保险数据库的队列研究纳入2015至2017年接受BRAF/MEK抑制剂一线治疗的1028例晚期黑色素瘤患者,其中361例(35.1%)同时使用质子泵抑制剂(PPI)。经重叠权重法平衡基线特征后,PPI联合使用与至治疗终止时间(加权HR 1.03,95%CI 0.86-1.24)及总生存期(加权HR 1.11,95%CI 0.88-1.39)缩短均无显著关联。

要点

  • 在转移性黑色素瘤患者中,同时使用PPI与BRAF/MEK抑制剂未显示与更差的至治疗终止时间或总生存期相关。
  • PPI使用者合并症更多且转移性疾病更严重,经重叠权重法平衡后上述关联仍无统计学显著性。
  • 将人群限制于接受达拉非尼治疗者或仅纳入细胞色素抑制作用较强的PPI时,结果一致。

核心结论

  • 在基于人群的晚期黑色素瘤队列中,同时使用PPI与BRAF/MEK抑制剂与更差结局无显著关联。

研究设计与样本

  • 使用法国国家健康保险数据库,选取2015至2017年间接受BRAF/MEK抑制剂作为一线治疗的晚期黑色素瘤患者。
  • 比较同时暴露与未暴露于PPI患者的至治疗终止时间(TTD)和总生存期(OS),并采用基于倾向评分的重叠权重法平衡基线特征。

主要发现

  • 转移性黑色素瘤队列共纳入1028例接受BRAF/MEK抑制剂的患者,其中361例(35.1%)使用PPI。
  • PPI使用者合并症更多且转移性疾病更严重。
  • 平衡转移部位与合并症后,同时使用PPI与至治疗终止时间缩短无显著关联(加权HR 1.03,95%CI 0.86-1.24)。
  • 同时使用PPI与总生存期缩短无显著关联(加权HR 1.11,95%CI 0.88-1.39)。
  • 将人群限制于接受达拉非尼治疗者或仅纳入细胞色素抑制作用较强的PPI时,结果一致。

关键数值与推荐

  • 美国食品药品监督管理局表示,PPI对达拉非尼在转移性黑色素瘤患者中疗效的影响尚不明确。
  • 欧洲肿瘤内科学会建议接受达拉非尼治疗的患者避免使用PPI(预防性措施)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proton-pump inhibitors (PPIs) are commonly used by patients with cancer, although they could reduce the absorption of oral anticancer targeted therapies. The US Food and Drug Administration states that the effect of PPIs on the efficacy of dabrafenib use by patients with metastatic melanoma is unknown. As a precautionary measure, the European Society for Medical Oncology recommends avoiding PPIs for patients receiving dabrafenib. OBJECTIVES: To determine the effect of the concomitant use of PPIs and BRAF/MEK inhibitors in patients with metastatic melanoma. METHODS: Patients with advanced melanoma receiving BRAF/MEK inhibitors as first-line treatments between 2015 and 2017 in France were selected using the French National Health Insurance database. We compared time-to-treatment discontinuation (TTD) and overall survival (OS) according to concomitant PPI exposure. We balanced the baseline characteristics of patients exposed and nonexposed to PPIs using an overlap weighting method based on a propensity score. RESULTS: The metastatic melanoma cohort comprised 1028 patients receiving BRAF/MEK inhibitors, including 361 (35.1%) patients using PPIs. PPI users had more comorbidities and a more severe metastatic disease. After having equally distributed metastatic sites and comorbidities across patients exposed and nonexposed to PPIs, concomitant PPI use was not associated with shorter TTD [weighted hazard ratio (wHR) 1.03, 95% confidence interval (CI) 0.86-1.24] or OS (wHR 1.11, 95% CI 0.88-1.39). Consistent results were observed when restricting the population to patients receiving dabrafenib, or when narrowing exposure to PPIs with stronger inhibition of cytochromes. CONCLUSIONS: In a population-based cohort of patients with advanced melanoma, the concomitant use of PPIs and BRAF/MEK inhibitors was not associated with worse outcome.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Poizeau F, Balusson F, Lemaitre F, et al. The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma. Br J Dermatol. 2023. PMID: 36760148. doi:10.1093/bjd/ljac085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。